Live Chat

交易 BioNTech BNTX

BioNTech實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%): 開倉

最新新聞

Christine Voong 2024 Dec 24, 10:19

美元匯率持續走高,聯準會鷹派立場支撐強勢;歐元及英鎊面臨壓力

Christine Voong 2024 Dec 24, 05:28

黃金價格走勢微幅上揚,美元強勢施壓,聯準會利率政策前景未明

Christine Voong 2024 Dec 24, 04:23

週二亞洲股市微幅上揚,美元強勢施壓全球市場,聯準會降息前景仍為關注焦點

So Ze Dong 2024 Dec 24, 01:00

週一科技股帶美股穩健上漲,分析師對於 “聖誕行情” 保持樂觀態度

Christine Voong 2024 Dec 23, 10:20

高通股價在贏得關鍵法律戰後上漲,市場前景明朗

Christine Voong 2024 Dec 23, 05:30

日本本田與日產合併消息提振市場,美國通膨數據放緩推動亞洲股市上漲

Christine Voong 2024 Dec 23, 03:00

美股指數期貨上揚,通膨降溫與聯準會利率前景牽動S&P 500指數、道瓊斯工業指數與納斯達克指數走勢

So Ze Dong 2024 Dec 23, 01:00

PCE通脹數據低於預期支撐美股指數大漲,市場對於「聖誕行情」維持樂觀態度

聯絡方式

點差

0.9554

點差(%)

0.8398 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-17:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

27212888064

流通股份

239740000

收益日期(下一個)

0000-00-00

現金殖利率 

2022-06-17

除息日

2022-06-02

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-2.01

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相關工具

資產
出售
購買
更改(%):
查看所有金融工具
Trustpilot
Live Chat